Aurobindo Pharma gets approval from USFDA for hypertension drugs
Aurobindo Pharma’s hypertension drug, the generic Telmisartan tablets in the strengths of 20 mg, 40 mg, and 80 mg, has got an approval from the USFDA.
Telmisartan tablets, which will be manufactured and marketed by Aurobindo Pharma in the US market are indicated in the treatment of essential hypertension and has an estimated market size of USD 92 million for the 12 months ending July 2015 according to IMS health, Aurobindo Pharma said.
The approved Abbreviated New Drug Application (ANDA) is bioequivalent to Boehringer Ingelheim Pharmaceuticals Inc's Micardis tablets, it added.
"This is the 46th ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing oral non- antibiotic products," it added.
Aurobindo now has a total of 211 ANDA approvals (183 final approvals including 9 from Aurolife Pharma LLC and 28 tentative approvals) from the USFDA, the company said.
Telmisartan tablets, which will be manufactured and marketed by Aurobindo Pharma in the US market are indicated in the treatment of essential hypertension and has an estimated market size of USD 92 million for the 12 months ending July 2015 according to IMS health, Aurobindo Pharma said.
The approved Abbreviated New Drug Application (ANDA) is bioequivalent to Boehringer Ingelheim Pharmaceuticals Inc's Micardis tablets, it added.
"This is the 46th ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing oral non- antibiotic products," it added.
Aurobindo now has a total of 211 ANDA approvals (183 final approvals including 9 from Aurolife Pharma LLC and 28 tentative approvals) from the USFDA, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.